Zydus USFDA Approval, October 21, 2026: First Generic of Bayer’s Climara Pro Patch

The Zydus USFDA approval that came through on Wednesday, October 21, 2026 is a small product on paper, but it has a twist that makes it more interesting than the usual ANDA filing. Zydus Lifesciences told the exchanges that the US regulator has given final approval to its generic Estradiol and Levonorgestrel Transdermal System, 0.045 mg/0.015 mg per day, and that the product carries a Competitive Generic Therapy (CGT) tag. That tag is what could give it a 180-day head start.

The reference drug is Bayer’s Climara Pro patch. The US Food and Drug Administration, in its own announcement dated October 20, called this the first generic of Climara Pro and said it approved Zydus Pharmaceuticals (USA) Inc.’s version the previous day.

What the Zydus USFDA approval covers

Here’s what the company’s press release filed with BSE and NSE says, point by point:

• Product: Estradiol and Levonorgestrel Transdermal System, 0.045 mg/0.015 mg per day, approved under an Abbreviated New Drug Application (ANDA).
• Exclusivity: the ANDA is designated a CGT, so the product is eligible for the 180-day exclusivity available to certain first approved applicants under that pathway, subject to US law. Any such period would start only when the product is first commercially marketed.
• Use: mainly to treat moderate to severe menopause symptoms, and also to prevent osteoporosis in postmenopausal women.
• Manufacturing: the group’s plant at Moraiya, near Ahmedabad in Gujarat.
• Market size: annual US sales of roughly USD 45.7 million, according to IQVIA MAT data for August 2026 cited by the company.
• Pipeline count: 458 approvals in total, and 516 ANDAs filed with the USFDA so far, as of September 30, 2026.

The filing was signed by company secretary Dhaval N. Soni and reached the exchanges shortly after 11 am on October 21.

Why a patch and a CGT tag matter

A lot of the US generic approvals Indian drugmakers announce are for oral tablets and capsules. This one is a weekly skin patch, and the CGT tag is the part that stands out, because it makes the product eligible for a 180-day exclusivity period once it is launched. Put those two together and we think this approval deserves a little more attention than its size suggests.

The FDA’s note adds some useful context. It describes the patch as a once-a-week therapy combining an estrogen and a progestogen, meant for women with an intact uterus. The progestogen is there to reduce the risk of endometrial hyperplasia linked to estrogen alone. The agency also pointed out that nine out of ten prescriptions filled in the US are for generics.

Still, keep the scale in view. A market of about USD 45.7 million is modest for a company of Zydus’s size, and the exclusivity window only opens once the product is actually launched. The company hasn’t given a launch date in the filing, so the real test is when it ships and how pricing holds up once others follow.

What to watch next

For the stock, the next useful signals are a launch announcement and any commentary on US generics in the coming quarterly numbers. Pharma names have had plenty of regulatory news lately; we covered Dr Reddy’s Zytorvi approval from the DCGI and the forensic audit Alkem ordered on October 21. If you track these filings regularly, our guide on how to analyse quarterly results helps link approvals like this to what eventually shows up in revenue.

Sources: Zydus Lifesciences press release and covering letter filed with BSE and NSE (October 21, 2026); US FDA press announcement (October 20, 2026).

Disclaimer: This article is for information and education only and is not investment advice. Please do your own research or consult a SEBI-registered adviser before making any investment decision.